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Cellular therapies are becoming increasingly important in treating cancer, hematologic 
malignancies, autoimmune disorders, and damaged tissue.  These therapies are becom-
ing more effective and are being used more frequently, but they are also becoming more 
complex. As a result, quality testing is becoming an increasingly important part of cellular 
therapy. Cellular therapies should be tested at several points during their production. The 
starting material, intermediate products and the final product are usually analyzed. 
Products are evaluated at critical steps in the manufacturing process and at the end of 
production prior to the release of the product for clinical use.   In addition, the donor of 
the starting biologic material is usually evaluated. The testing of cellular therapies for sta-
bility, consistency, comparability and potency is especially challenging.  We and others 
have found that global gene and microRNA expression analysis is useful for comparability 
testing and will likely be useful for potency, stability and consistency testing. Several exam-
ples of the use of gene expression analysis for assessing cellular therapies are presented.
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INTRODUCTION
  Cellular therapies are becoming increasingly important 
in treating cancer, hematologic malignancies, autoimmune 
disorders, and damaged tissue. These therapies include hema-
topoietic stem cell transplantation (HSC), adoptive immune 
therapy for cancer, gene therapy for the treatment of in-
herited immune deficiencies, and bone marrow stromal cell 
(BMSC) therapy for the treatment of ischemic heart disease.  
The contemporary cellular therapies now used involve the 
processes of cell selection, stimulation, culture, expansion, 
and gene insertion. Many even involve a combination of 
these processes. But while these therapies are becoming more 
effective and are being used more frequently, they are also 
becoming more complex. 
  HSC transplants have been used to treat acute leukemia 
and lymphoma for more than 40 years. Initially, this therapy 
involved the transplantation of marrow aspirated from synge-
neic or HLA-compatible sibling donors. HSC transplantation 
has changed to include additional graft sources from places 
such as umbilical cord blood and mobilized peripheral blood 
stem cells collected by apheresis. Each type of hematopoietic 
stem cell graft requires a different type of processing and 
the grafts are often highly manipulated. To reduce the risk 
of graft-versus host disease, T cells are often depleted or 
CD34+ cells are isolated and transplanted. HSC trans-
plantation now includes the administration of cells in addi-
tion to HSCs. The administration of lymphocytes or T cells 
from allogeneic donors following transplantation is often 
used to treat relapsed leukemia. These donor lymphocyte 
infusions, or DLIs, are also given to speed immune recon-
stitution and prevent leukemia or cancer relapse. In some 
cases, leukocytes that have been selected and stimulated 
are used for donor lymphocyte infusions [1, 2].
  The use of cellular therapies to treat cancer is also growing 
rapidly. Immune cells, isolated and expanded from surgically 
resected tumors, are an effective cancer adoptive immune 
therapeutic tool. The administration of these tumor infiltrat-
ing leukocytes, or TIL cells, to patients with metastatic mela-
noma results in an objective clinical response rate of 31% 
to 35% [3]. When TIL cell therapy for melanoma is combined 
with myelosuppressive chemotherapy (with stem cell rescue 
using autologous CD34+ cells isolated from G-CSF-mobilized 
PBSC products), the response rates increase to 49% to 72% Korean J Hematol 2010;45:14-22.
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Table 1.  Summary of points where cellular materials or donors are 
often evaluated during the production process and the types of 
analyses that are often performed.
Material tested Types of assays
Donor ㆍHealthy history screening
ㆍTesting for infectious diseases
ㆍABO blood grouping
ㆍHLA typing
Starting material ㆍCell counts
ㆍViability
ㆍPurity
ㆍSurface marker evaluation
In-process testing ㆍCell counts
ㆍViability
ㆍPurity
ㆍSurface marker evaluation
ㆍSterility 
Final product ㆍCell counts
ㆍViability
ㆍPurity
ㆍSurface marker evaluation
ㆍSterility 
ㆍPotency
[4]. Autologous NK cells are also being used to treat leukemia, 
lymphoma, and cancer [5-8]. In some cases NK cells are 
expanded more than 100-fold before they are administered 
to patients [7]. In addition to the administration of these 
immune cells, dendritic cells (DCs) as profession and highly 
effective antigen presenting cells are being used for several 
types of cancers vaccines after in vitro pulsing. Both im-
mature and mature DCs are being used.
  The improved clinical outcomes associated with cellular 
therapies has lead to broader utilization and as are result, 
quality testing is becoming an increasingly important part 
of cellular therapy. Most clinical cellular therapy products 
are initially developed and tested in clinical trials at one 
center, but as soon as a therapy is found to be effective 
at a single institution, it is tested at other centers and even-
tually, in multicenter clinical trials. In order for cellular 
therapies to be exported from one center to another for 
further clinical evaluation, it’s critical to have mechanisms 
in place to ensure that the cell collection and processing 
procedures yield safe, effective, and comparable products 
at all centers. Products manufactured at all centers should 
also be of similar composition, purity, and potency. 
QUALITY TESTING OF CELLULAR THERAPIES
  Cellular therapies should be tested at several points during 
their production (Table 1) thus, the starting material, inter-
mediate products, and the final product are usually all 
analyzed. Products are evaluated at critical steps in the manu-
facturing process (in-process testing) and at the end of pro-
duction prior to the release of the product for clinical use 
(lot release testing). The results of in-process and lot release 
assays should fall within specified ranges and meet pre-
determined acceptance criteria before the product can be 
released for clinical use. The starting material and final prod-
uct are generally more thoroughly evaluated than the inter-
mediate products. In addition, the donor of the starting bio-
logic material is usually evaluated as well.
1. Donor testing
  The potential donor’s medical history is generally assessed. 
Subjects who have a history of an infectious disease that 
maybe transmitted by the transfusion of blood or cellular 
therapy, or have been exposed to such an agent, are often 
prevented from donating. The donor of the starting material 
is also generally tested at molecular, antigen and antibody 
levels for possible exposure to infectious agents that could 
be transmitted to the cell therapy recipient by the product. 
The donor’s cells, that are used to manufacture products 
for allogeneic use, for HIV, hepatitis B virus (HBV), and 
hepatitis C virus (HCV) and may be tested for other blood 
borne pathogens. The specific pathogens evaluated and the 
assays used vary between countries and sometimes even 
within countries. It is usually less critical to test people 
who are donating cells for themselves. However, autologous 
donors are often tested for HIV, HBV, and HCV since special 
precautions may be necessary to protect other patients’ cel-
lular therapies and the laboratory staff when processing and 
storing products from infected donors.
2. Testing the starting material
  The cellular starting material is typically tested for volume 
and cell concentration. Some sort of documentation is usually 
made, indicating that a sufficient quantity of the desired 
cell type has been collected. The assessment of the cell type 
collected may then involve evaluations based on cell size, 
shape, and morphology or the evaluation of cell surface mark-
ers by flow cytometry. The purity of the cells in the starting 
material is also often evaluated by flow cytometry. In addi-
tion, cell viability is also generally measured by dye exclusion 
assays. 
  Identity testing is usually performed on the starting materi-
al as well. Identity testing measures genetic markers that 
can be used to confirm that the product’s distinctive character 
which can be used to identify the specific cells at any point 
in the production process. This is usually achieved by testing 
for HLA antigens or by ABO blood grouping. 
  In some cases the starting material is tested for sterility. 
Sterility testing may include a gram stain, endotoxin testing, 
and microbial cultures. The starting material may also be 
tested for mycoplasma using culture or PCR assays. 
3. In process testing
  During the intermediate processing steps, the product may 
be tested for volume, cell concentration, cell number, purity, 
and sterility. It may also be important to document the 
specific cell populations (such as leukemia or lymphoma 
cells) that are no longer present. The cells are often charac-
terized by flow cytometry. Korean J Hematol 2010;45:14-22.
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4. Final product testing
  The testing of the final product generally includes measur-
ing the quantity and purity of the cells. But if the cells 
have been cultured or extensively manipulated, they should 
also be tested for sterility. 
  In addition to the tests discussed above, another important 
aspect of evaluating the final product is potency testing. 
Potency testing involves the quantitative measure of bio-
logical activity of a product. The biological activity should 
describe the ability of a product to achieve a defined bio-
logical effect. The biological activity measured should be 
closely related to the product’s intended biological effect 
and ideally, it should be related to the product’s clinical 
response [9-11]. Measurement of the potency of a product 
is not the same as measuring clinical efficacy. Rather, it 
is a means to control product quality. 
  Potency assays for cellular products usually take a consid-
erable amount of time to develop. Generally, the develop-
ment of potency assays is progressive and begins during 
preclinical and early clinical development. A potency assay 
should be validated and already in place prior to phase III 
clinical trials involving a specific cellular therapy [9, 10]. 
5. Other quality measures
  3 other important measures of cell therapy quality are 
stability, consistency, and comparability testing. These meas-
ures are not performed on all products but are still an im-
portant part of product development and ongoing product 
evaluation. 
  1) Stability testing
  Stability testing is performed to ensure that products re-
main potent at the time of administration. Since the life 
of most cells is relatively short (sometimes only hours), stabil-
ity testing must document cells that are still viable and potent 
at the end of the several hours required to release the product 
from the cell therapy laboratory’s inventory, transport the 
product from the laboratory to the patient’s bedside, and 
administer the product to the recipient. 
  2) Consistency testing
  Using the same protocol, there may still be considerable 
lot-to-lot variability in clinical cellular therapies produced. 
Consistency testing, therefore, measures variability among 
products. This variability may be due to differences in starting 
material or differences in the manufacturing process. Differ-
ences in the starting material may be due to variability in 
the collection process. There may also be differences in the 
starting material as a result of variability among donors with 
genetic differences. Genetic polymorphisms in cytokines, 
growth factors, and their receptors affect the cellular immune 
response [12-15]. It is likely that these polymorphisms affect 
the response of cells to cytokine and growth factor stim-
ulation in vitro and the behavior of cells during culture. 
Epigenetic changes may also be important. The same type 
of cells obtained from different donors, time points, and 
physiological conditions could vary significantly due to ge-
netic heterogeneities, epigenetic differences, or transcription 
regulation diversities. When material is collected from pa-
tients for autologous use, there may also be differences due 
to the patients’ disease stage or type, or due to previous 
therapies.
  Variability in the product could also be introduced in 
the manufacturing process due to differences in equipment, 
supplies, reagents, and the techniques used by the laboratory 
staff. Variability due to such production factors can be as-
sessed by measuring the consistency of multiple products 
manufactured from the same donor or patient. Differences 
due to donor factors can be assessed by comparing the differ-
ences among multiple products manufactured from each 
donor. Environmentally caused differences can be measured 
by comparing multiple products manufactured from the same 
donor or patient at different time points or in different 
batches. 
  3) Comparability
  It is often necessary to compare products manufactured 
using different methods. During the scale up of the initial 
production of a cellular therapy, it is necessary to demon-
strate that cells produced on a small scale are the same 
as those produced with a modified method used for manu-
facturing cells on a much larger scale. The scaling up of 
methods often requires the use of different containers, re-
agents, instruments, and media. These changes could affect 
the potency of the final product. 
  Once a specific cellular therapy is being manufactured 
for patient use, it may be necessary to change the manufactur-
ing process or manufacturing facility due to a change or 
lack of availability of a reagent, device, or instrument used 
in the manufacturing process. Cells manufactured using a 
revised method should be compared with those produced 
using the original method to ensure that the 2 methods 
yield comparable cells. 
6. Need for molecular testing
  The testing of cellular therapies for stability, consistency, 
comparability and potency is challenging and their evalua-
tion requires the measurement of important functions of 
the cellular therapies. The function of many cellular therapies 
is very complex and multiple functions may be required 
for a therapy to be effective such as trafficking, antigen 
presentation, cytokine and growth factor release, differ-
entiation, maturation, in vivo expansion, and cytotoxicity. 
Dendritic cells must traffic to lymph nodes, present antigens, 
and stimulate T cells. Hematopoietic stem cells must home 
to their niche, proliferate, and differentiate. For most cell 
therapies, their critical functions are not completely under-
stood and for some cell therapies, the critical functions are 
not known. Those unknown functions can only be under-
stood by the application of high throughput technologies 
which can uncover the entire cell transcriptome and shed 
light on what the cell intends to do. We have applied global 
gene and microRNA (miR) expression analysis to cell therapy 
products and have found that they are very useful for com-
parability testing and will likely be useful for potency, stabil-
ity and consistency testing. Korean J Hematol 2010;45:14-22.
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Table 2.  Comparison of high throughput molecular assays for assessing cellular therapies with other analytical assays.
High throughput molecular assays Other analytical assays
Type of assays
ㆍGene expression analysis
ㆍMicroRNA expesssion analysis
Type of assays
ㆍFlow cytometery
ㆍELISA
Strengths
ㆍFew cells are needed
ㆍCells can be cryopreserved before testing
ㆍVery large numbers of biomarkers can be assessed
ㆍUseful for identifying new biomarkers
Strengths
ㆍAssays are standardized
ㆍAssays are quantative
ㆍCan be completed quickly
Weaknesses
ㆍPlatforms are not yet standardized
ㆍIt may take several days to complete testing and analyze the data
Weaknesses
ㆍOften fresh cells must be tested
ㆍA limited number of biomarkers can be tested at one time
  There are several benefits to using gene and miR expression 
profiling for assessing cellular therapies (Table 2). First, since 
most cellular therapies are patient-specific, there is usually 
a limited quantity of suitable source material and therefore, 
a limited amount of final product available for testing. The 
starting materials for most cellular therapies are cells col-
lected from human subjects. Generally, an entire production 
lot of a cellular therapy is usually administered to a single 
patient and the use of large quantities of the product for 
testing may adversely affect the dose and clinical effective-
ness of the product. This limitation on the quantity of materi-
al available prevents the use of some assays and/or limits 
the number of factors that can be tested.
  A practical advantage of gene expression microarrays over 
other analytical assays such as ELISA or flow cytometry 
is that it requires very few cells. Enough RNA can be isolated 
from 1×10
4 to 1×10
6 cells for analysis with a global gene 
cDNA expression microarray [16]. Microarrays with 15,000 
to 40,000 genes or oligonucleotide probes have been used 
clinically to characterize lymphomas, [17] prostate cancer, 
[18] ovarian cancer, [19] small cell lung cancer, [20] melano-
ma, [21] and many other cancers. Since gene expression 
microarrays simultaneously measure the expression of thou-
sands of genes, they capture a snap shot of all possible gene 
expression signatures that are associated with cellular func-
tion and hence, could be a very important tool for assessing 
the potency of cellular therapies. The comprehensive nature 
of gene expression microarray analysis makes them ideal 
for measuring both expected and unexpected cell functions. 
This is particularly important for the analysis of cells with 
complex and multiple critical functions such as dendritic 
cells (DCs), cytotoxic T cells, embryonic stem cells, HSCs, 
and bone marrow stromal cells (BMSCs). 
  MicroRNA expression arrays have also been used to access 
cellular therapies. MicroRNAs are an abundant class of en-
dogenous non-protein-coding small RNAs of 19 to 23 nucleo-
tides that are derived from pre-miRNA of 60 to 120 nucleo-
tides. Mature miRNAs negatively regulate gene expression 
at the post transcriptional level. They reduce the levels of 
targeted transcripts as well as inhibit protein translation.  
More than 800 human miRNAs have been identified so far 
[22]. In general, miRNAs are phylogenetically conserved 
and therefore, have conserved and defined post transcription 
inhibition functions. Some miRNAs are expressed through-
out an organism but most are developmentally expressed 
or are tissue-specific.
  MicroRNAs also play an important role in many cellular 
development and metabolic processes including devel-
opmental timing, signal transduction, tissue differentiation, 
and cell maintenance. Most miRNAs are tissue specific. For 
example the expression of miR-1 is restricted to the heart 
[23] while miR-223 is limited to granulocytes and macro-
phages [24]. Recently, miRNA have been found to play a 
role in stem cell self-renewal and differentiation. Several 
different miRNAs are involved with the differentiation of 
hematopoietic progenitor cells. miR-155, for instance, is im-
portant in preventing the differentiation of CD34+ cells to-
ward myeloid and erythroid cells [25] and in the maturation 
of DCs [26]. In addition, miR-221 and miR-222 prevent 
the differentiation of hematopoietic stem cells into erythroid 
progenitors [27] while miR-181 is involved in the control 
of lymphopoiesis [24]. 
  There are however some limitations concerning the use 
of gene and miR expression microarrays for potency testing. 
These platforms are still evolving and it is not always possible 
to compare the results obtained with different platforms. 
Gene and miR expression microarray analysis involves multi-
ple steps including RNA isolation, amplification, fluorescent 
labeling, hybridization, and data analysis. It is impossible 
with the current technology to complete the whole proce-
dure within a few hours and thus global expression micro-
arrays cannot yet be used for lot release testing. However, 
if global microarrays can identify specific sets of gene or 
miR whose expression is associated with potency, tailored 
chips or quantitative real-time PCR kits that only assess 
specific “potency genes” could be developed and used for 
lot release testing. 
  Despite these limitations, we and many others have found 
these assays to be very useful in assessing cellular therapies. 
We present several examples of the use of gene expression 
analysis for assessing cellular therapies.Korean J Hematol 2010;45:14-22.
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EXAMPLES OF THE USEFULNESS OF 
MOLECULAR ASSAYS
1. In process testing
1) Predicting the confluence of human embryonic kidney 
293 cells
  Gene expression microarrays can be utilized to predict 
the quality of cells used to manufacture biological products. 
Human embryonic kidney (HEK) 293 cells are often used 
to manufacture products such as adenoviral gene therapy 
vectors and vaccines [28]. These cells can be grown in bio-
reactors, tissue culture flasks, and roller bottles. However, 
when HEK 293 cells have grown to form a confluent mono-
layer, their phenotype changes as does the quality of the 
vector or vaccine produced by these cells. Cell confluence 
can be readily assessed by visual inspection of cells grown 
in flasks and roller bottles, but for cells grown in bioreactors, 
the assessment of confluence by visual inspection is not 
always possible or clear. Gene expression profiling can be 
used to identify genes whose expression predicts cell con-
fluence [28]. HEK 293 cells that have been grown to 90% 
confluency have a unique gene expression signature com-
pared to those grown to 40% confluency and therefore a 
set of 37 of these signature genes is able to predict that 
quality and confluence of HEK 293 cells. 
2) Analysis of embryonic stem cell differentiation
  Human embryonic stem cells (hESCs) have the potential 
to be useful for a number of clinical applications. Since cul-
tured hESCs may undergo spontaneous differentiation, it 
is important to determine if cultured hESCs have maintained 
their stem cell qualities or if they have begun to acquire 
properties of more differentiated cells. Gene expression 
profiling may thus be useful for assessing cultured hESCs 
since it has been used to identify genes that are uniquely 
expressed by hESCs [29]. Player et al have found that 1715 
genes were differentially expressed between hESCs and dif-
ferentiated embryonic cells [29]. This finding is likely to 
be useful in determining if cells in culture have maintained 
their embryonic stem cell characteristics.
  Embryonic stem cells must be differentiated before they 
can be used clinically. One of the first steps in the differ-
entiation of hESCs into mature cells and tissues for clinical 
use is the production of embryoid bodies (hEBs), which 
involves the aggregation of embryonic cells but the pre-
vention of the differentiation o f  c e l l s  i n t o  g e r m  l i n e s  b y  
plating them onto a non-permissive substrate. After these 
hEBs are isolated, they can be induced to generate several 
different types of cells including hematopoietic cells, neuro-
nal, myogenic, and cardiac muscle cells. A comparison of 
gene expression profiles of hESCs and hEBs has found 194 
genes whose expression was more than 3-fold greater in 
hEBs than in hESCs [30]. This unique set of genes should 
also be useful in assessing hESCs differentiation.
  hESCs and hEBs also have unique miR expression profiles. 
Unique miRNA expression patterns have been identified in 
undifferentiated hESCs. A comparison of miRNA expression 
profiles among samples from hESCs and hEBs and five differ-
ent adult cell types revealed that 104 miRNAs differentially 
expressed miRNA [31]. Seven miRs within miR-302 cluster 
on chromosome 4 and 21 miRs within the miR-520 cluster 
on chromosome 19 were highly expressed in undifferentiated 
hESCs compared to hEBs and the adult cells. The members 
of these 2 clusters share a consensus 7-mer seed sequence 
and their targeted genes had overlapping functions. 
Therefore, miR in the miR-302 and miR-520 clusters are 
likely to be biomarkers for hESC differentiation. Interest 
in reprograming adult cells to function back to pluripotent 
stem cells, induced pluripotent stem (IPS) cells, for re-
generative medicine applications is growing and gene and 
miR expression analysis will also likely be effective in assess-
ing these cells. 
2. Comparability testing
  We have also found gene expression analysis to be useful 
for comparability testing. By applying gene expression analy-
sis we have shown that immature DCs made from fresh 
PBMCs are a similar transcription profile to those made 
from stored PBMCs [32] and that mDCs produced with three 
different maturation protocols share similar transcriptome 
profiles [33]. The conclusion that two types of immature 
DCs and three types of mDC were similar could only be 
made when genome wide whole transcripts were analyzed. 
This suggests that gene expression analysis is useful for com-
parability testing. 
1) Immature DCs from stored PBMCs
  The production of clinical cellular therapies often involves 
multiple centers. Cells such as PBMCs are collected from 
a donor or patient at one center and is then shipped to 
a specialized cellular therapy laboratory where they are proc-
essed and become DCs. When production of the cellular 
therapy at the centralized center is complete, the product 
is shipped to the site where it is administered to a specific 
patient. But the centralized cell processing laboratory may 
be hundreds or thousands of miles from the collection center 
and it may even take 48 hours or more after the collection 
is complete for the starting cellular material to reach the 
cell processing laboratory. 
  To evaluate whether immature DCs (iDCs) produced from 
fresh PBMCs are similar to those produced from PBMCs 
that have been stored for 48 hours at 4
oC and treated with 
GM-CSF and IL-4, we evaluated gene expression profiles 
of both types of iDCs [32]. Global gene expression analysis 
revealed that 48 hours of storage at 4
oC had some effects 
on the PBMCs, but had no effect on the iDCs. The striking 
similarity in gene expression among iDCs derived from fresh 
and stored PBMCs suggests that there is no difference in 
the function of these cells and that the changes in PBMCs 
during storage did not effect the ability of these cells to 
be used to produce iDCs.
2) Comparison of DC maturation protocols
  Some adoptive immune therapy studies have used iDCs, 
however, mature DCs (mDCs) are increasingly being used Korean J Hematol 2010;45:14-22.
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for clinical immune therapy because they express increased 
levels of co-stimulatory molecules, produce greater quantities 
of cytokines, and are superior in the stimulation of cytotoxic 
T-cell response compared to iDCs [34]. mDCs with effective 
anti-tumor responses have high levels of expression of 
co-stimulatory molecules CD80, CD83, and CD86, have high 
migratory activity in response to the lymphoid organ chemo-
kines CCL19 and CCL21, [35, 36] and have high capacity 
to produce interleukin-12p70 (IL-12p70) which is the major 
factor driving Th1 reactions [37, 38].
  To produce mDCs, imDCs are treated with various stimuli 
known to induce DC maturation [37, 39, 40]. DC maturation 
can be induced using inflammatory signals such as tumor 
necrosis factor (TNF), interleukin-1beta (IL-1β), or bacterial 
derivatives such as lipopolysaccharide (LPS). Double strand-
ed RNA, interferons and postaglandins can also induce DC 
maturation [41, 42]. The “gold standard” DC maturation 
cocktail has been IL-1β, IL-6, TNF-α, and prostaglandin 
E2 (PGE2) [43]. This cocktail generates mDCs with high 
co-stimulatory and migratory functions, however they pro-
duce relatively low levels of IL-12 [44]. As a result, a number 
of  ex vivo maturation cocktails have been developed for 
clinical use that generate mDC that produce higher levels 
of IL-12p70 than the IL-1β, IL-6, TNF-α and PGE2 cocktail 
[37].
  LPS is a toll-like receptor (TLR) ligand and a microbial 
compound originating from the outer membrane of the 
gram-negative bacterial cell wall. It is being used as a DC 
maturation stimulant since it is a good inducer of IL-12p70 
production [38, 40]. LPS stimulates Toll-like receptor 4 
(TLR4), mediates the activation of nuclear factor-kappa B 
(NF-kB) and mitogen activated protein kinases (MAPKs), 
and finally initiates DC maturation [45, 46]. Another im-
portant DC maturation stimulant is IFN-γ which enhances 
the TLR signaling pathway and up-regulates DC in-
flammatory cytokines. It has been also reported that IFN-γ  
can significantly augment IL-12p70 production [47].
  In order to determine if the maturation of DCs by the 
combination of LPS plus IFN-γ can be improved by the 
addition of IL-1β or IL-1β plus TNF-α, we compared 
mDCs produced from PBMCs with these agents. Monocyte- 
derived DCs were prepared by the elutriation of monocytes 
from PBMCs followed by incubation in GM-CSF and IL-4 
to produce iDCs. To produce mDCs, the iDCs were stimulated 
with LPS plus IFN-γ; LPS, IFN-γ, plus IL-1b; and LPS, 
IFN-γ, IL-1β plus TNF-α. All three DC maturation cock-
tails produced mDCs that expressed greater levels of com-
monly used markers of DC maturation: CD80, CD83, CD86, 
and CCR7. In addition, there were no differences in the 
production of IL-12p70 and IL-10 by the mDCs produced 
with the 3 different cocktails.
  Although traditional assays used to assess DCs, flow cy-
tometry and ELISA, did not reveal any differences between 
the three groups of mDCs, the function of DCs is complex 
and still not completely understood. It is likely that DC 
function is influenced by many other factors in addition 
to the expression of CD80, CD83, CD86, and CCR7 and 
the production of IL-12p70 and IL-10. To more thoroughly 
compare the mDCs produced with the three maturation cock-
tails, we analyzed the mDCs using gene expression micro-
arrays with more than 36,000 probes. While we found that 
9,576 genes were differentially expressed between iDCs and 
mDCs, the expression of only 13 genes differed between 
the three groups of mDCs. Multivariate analysis also sug-
gested that there were more differences between DCs from 
different donors than between maturation cocktails [33]. 
These results thus show that there is no benefit of adding 
IL-1β and TNF-α to the LPS plus IFN-γ DC maturation 
cocktail.
3. Consistency testing
  Global gene expression analysis may be an excellent tool 
for assessing the consistency of cellular therapies. In the 
study described above, in which we evaluated mDCs pro-
duced with three different maturation cocktails (LPS plus 
IFN-γ; LPS, IFN-γ plus IL-1β; and LPS, IFN-γ, IL-1β 
plus TNF-α) from six healthy subjects, the DCs clustered 
according to donor rather than maturation protocol (Fig. 
1). This result suggests that global gene expression profiling 
can distinguish differences due to donor variability. The 
ability of gene expression profiling to detect minor differ-
ences between healthy subjects will likely make this an ex-
cellent assay for consistency testing. 
  A number of cellular therapy production protocols involve 
the serial production and administration of cellular therapies 
produced from autologous cells. Global gene expression anal-
ysis should allow for the assessment of differences among 
multiple products produced from the same donor that may 
be due to problems or modifications in the cell therapy 
production procedure.
4. Potency testing
1) Potency testing of hematopoietic stem cells
  Potency assays used for HSC products should measure 
the ability of the product to reconstitute bone marrow hema-
topoietic cells and peripheral blood cells in the transplant 
recipient. The potency assay should also reflect the period 
of time that neutrophil, platelet, and red blood cell counts 
return to and remain above specified levels independent 
of transfusion therapy. 
  Liquid culture of long-term culture initiating cells (LTC- 
IC) and the repopulation of marrow in nonobese diabetic 
(NOD)/severe combined immunodeficiency (SCID) mice as-
says are considered to be the best measure of the quantity 
and quality of hematopoietic stem cells. However, these as-
says require highly specialized reagents, a highly trained 
staff, and several weeks to complete. As a result, these assays 
have seldom, if ever, been used as potency assays. The meas-
urement of myeloid, erythroid, and mixed colony formation 
in methylcellulose culture systems has been used for assessing 
bone marrow and PBSC HSC products, however, these assays 
take approximately 14 days to complete and do not produce 
reliable quantitative data. Traditionally, total nucleated cell 
counts were used to assess the potency of bone marrow Korean J Hematol 2010;45:14-22.
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Fig. 1. Global gene expression analysis separated immature dentritic 
cells (iDCs) and mature dentritic cells (mDCs) by donor rather than 
maturation cocktail. Three sets of iDCs were prepared from six healthy
subjects (donors 1 through 6) by culturing peripheral blood monocytes
with IL-4 and GM-CSF for 3 days. The iDC samples of each subject were 
matured by culture with one of three maturation cocktails: LPS plus 
IFN-γ(C1); LPS, IFN-γ  plus IL-1β(C2); and LPS, IFN-γ, IL-1β  plus 
TNF-α(C3). The 18 iDC and 18 mDC samples were analyzed by global
gene expression profiling with more than 36,000 oligonucleotide 
probes and the results were analyzed by unsupervised hierarchical 
clustering analysis. The iDC and mDC samples were in two separate 
clusters. Within these two clusters, the samples grouped according to 
subject. ANOVA analysis revealed that expression of 9,590 genes were
differentially expressed among donors, but only 13 genes were diffe-
rentially expressed among differentiation protocols [33].
and are still used as a measure of potency of umbilical cord 
blood components prepared for transplantation. The meas-
urement of CD34+ cells by flow cytometry has, however, 
become the universal assay for measuring the potency of 
HSC products. One limitation of the use of CD34+ antigen 
expression as a potency marker is that HSCs expressing CD34 
antigen do not represent a homogenous population. Several 
distinct subpopulations or phenotypes of CD34+ cells have 
been described [48]. Some subpopulations are more primitive 
while others are more likely to differentiate into myeloid 
cells, erythroid cells or megakaryocytes. 
  Recently, the agent plerixafor has been approved by the 
US Food and Drug Administration for use in combination 
with G-CSF to mobilize stem cells for autologous trans-
plantation. The mechanisms by which plerixafor and G-CSF 
alter HSC trafficking and mobilization are different, suggest-
ing that HSCs with different intrinsic properties may be 
mobilized by these agents. Plerixafor, as a CXCR4 antagonist, 
mobilizes HSCs within 6 hours [49-51] by disrupting the 
engagement of stem cell surface CXCR4 [49, 52, 53] with 
its ligand SDF-1 (CXCL12) which is expressed on marrow 
osteoblast [54, 55]. In contrast, G-CSF mobilizes stem cells 
indirectly by down-regulating the expression of CXCL12 
on marrow osteoblasts and by releasing neutrophil and mono-
cyte proteolytic enzymes including neutrophil elastase, cath-
epsin G, and matrix metalloproteinase-9 which in turn de-
grade important HSC trafficking and adhesion molecules 
c-kit, VCAM-1 and CXCR4 [56].
  To explore the possibility of using gene and miRNA ex-
pression profiles assess HSC potency, we used a rhesus mac-
aque HSC-mobilization model to compare CD34+ cells mobi-
lized by G-CSF, by plerixafor, and by the combination of 
G-CSF and plerixafor. The CD34+ cells were compared using 
global gene and miR expression analysis. While many of 
the same genes were up-regulated in CD34+ cells mobilized 
by either plerixafor or G-CSF, there were also a large number 
of genes expressed that differed [57]. G-CSF-mobilized 
CD34+ cells were more likely to express neutrophil and 
mononuclear phagocyte genes than those mobilized by 
plerixafor. In addition, G-CSF-mobilized CD34+ cells also 
e x p r e s s e d  h i g h  l e v e l s  o f  m i R - 1 5 5 ,  w h i c h  i s  e x p r e s s e d  i n  
maturing DCs [26, 58]. In contrast, plerixafor-mobilized 
CD34+ cells were more likely to express B, T, and mast 
cell genes. These results suggest that G-CSF mobilizes a great-
er proportion of HSCs that are committed toward myeloid 
differentiation while those mobilized by plerixafor are more 
likely to be committed toward B, T, and mast cells. 
  Surprisingly, the combination of plerixafor plus G-CSF 
mobilized a population of CD34+ cells that were distinct 
from CD34+ cells mobilized by either agent alone.  CD34+ 
cells mobilized by plerixafor plus G-CSF were more likely 
to express B cell and T cell genes than G-CSF-mobilized 
and plerixafor-mobilized CD34+ cells. In addition, plerixafor 
plus G-CSF-mobilized CD34+ cells were also remarkable for 
their increased expression of miR142-3p and miR-142-5p. 
miR-142-3p and miR-142-5p are highly expressed in T cells 
[59] and miR-142-3p has been found to be increased in 
childhood B-cell precursor acute lymphoblastic leukemia 
[60]. These results thus suggest plerixafor plus G-CSF mobi-
lizes a greater proportion of B and T cell precursors than 
either G-CSF or plerixafor alone. 
  Other studies have also found that plerixafor, G-CSF, and 
plerixafor plus G-CSF mobilize different types of CD34+ 
cells. In a mouse model, Pitchford and colleagues have found 
that G-CSF mobilized greater quantities of hematopoietic 
progenitor cells than plerixafor while plerixafor mobilized 
greater quantities of endothelial progenitor cells than G-CSF 
[61]. They also found that the combination of G-CSF plus 
plerixafor mobilized greater quantities of hematopoietic pro-
genitors than either agent alone, but not endothelial pro-
genitors. Additionally, Jin et al have found that HSCs in 
healthy subjects mobilized with plerixafor or plerixafor plus 
G-CSF differ from those mobilized by G-CSF alone [62]. 
Furthermore, flow cytometry analysis by Rettig and col-
leagues of CD34+ cells mobilized by Plerixafor alone identi-
fied a unique CD34
dimCD45RA+ subset that was not mobi-
lized by G-CSF alone [63]. The results of these studies demon-Korean J Hematol 2010;45:14-22.
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strate a role for gene and miR expression analysis for HSC 
potency testing. 
CONCLUSIONS
  As more and more new cellular therapies are being devel-
oped and used to treat an increasing variety of diseases and 
patients, the analysis of the quality of cellular therapies 
(including stability, consistency, comparability, and potency 
t e s t i n g )  i s  b e c o m i n g  a  c r i t i c a l  a n d  r e q u i r e d  p a r t  o f  t h e i r  
production. Existing assays such as function, flow cytometry, 
and ELISA are important, but gene and miRNA expression 
microarrays have the potential to become essential additions 
to the standard assays for assessing cellular therapies. Gene 
and miR assays have already been shown to be useful in 
comparability and stability testing. These assays are also well 
suited for assessment of the potency of cellular therapies 
in phase I and II clinical trials. During these early phase 
clinical trials, genes and miRs whose expression is found 
to be associated with critical biological function can be identi-
fied and evaluated as possible biomarkers of potency. 
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